APWA
BCLI

Atlas Private Wealth Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Atlas Private Wealth Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9
Closed -$1K – 669
2020
Q2 		$1K Buy
+9
New +$970 ﹤0.01% 631

Other funds holding BCLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Atlas Private Wealth Advisors's BCLI Position: Q3 2020 in Review

Atlas Private Wealth Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 9 shares — an estimated $1K sold.

Atlas Private Wealth Advisors first reported a position in BCLI in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

  • Atlas Private Wealth Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
  • Atlas Private Wealth Advisors sold 9 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $1K.
  • Atlas Private Wealth Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 1 quarter.
  • Atlas Private Wealth Advisors's BRAINSTORM CELL THERAPUTC position peaked at $1K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on Atlas Private Wealth Advisors's 13F filing for Q3 2020, filed 27 Oct 2020.